Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygens, Sammy, Hofsink, Quincy, Nijhof, Inger S, Goorhuis, Abraham, Kater, Arnon P, te Boekhorst, Peter A W, Swaneveld, Francis, Novotný, Věra M J, Bogers, Susanne, Welkers, Matthijs R A, Papageorgiou, Grigorios, Rijnders, Bart J, Heijmans, Jarom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384649/
https://www.ncbi.nlm.nih.gov/pubmed/35921542
http://dx.doi.org/10.1093/infdis/jiac334
_version_ 1784769456808919040
author Huygens, Sammy
Hofsink, Quincy
Nijhof, Inger S
Goorhuis, Abraham
Kater, Arnon P
te Boekhorst, Peter A W
Swaneveld, Francis
Novotný, Věra M J
Bogers, Susanne
Welkers, Matthijs R A
Papageorgiou, Grigorios
Rijnders, Bart J
Heijmans, Jarom
author_facet Huygens, Sammy
Hofsink, Quincy
Nijhof, Inger S
Goorhuis, Abraham
Kater, Arnon P
te Boekhorst, Peter A W
Swaneveld, Francis
Novotný, Věra M J
Bogers, Susanne
Welkers, Matthijs R A
Papageorgiou, Grigorios
Rijnders, Bart J
Heijmans, Jarom
author_sort Huygens, Sammy
collection PubMed
description BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.
format Online
Article
Text
id pubmed-9384649
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93846492022-08-18 Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial Huygens, Sammy Hofsink, Quincy Nijhof, Inger S Goorhuis, Abraham Kater, Arnon P te Boekhorst, Peter A W Swaneveld, Francis Novotný, Věra M J Bogers, Susanne Welkers, Matthijs R A Papageorgiou, Grigorios Rijnders, Bart J Heijmans, Jarom J Infect Dis Brief Report BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available. Oxford University Press 2022-08-04 /pmc/articles/PMC9384649/ /pubmed/35921542 http://dx.doi.org/10.1093/infdis/jiac334 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Huygens, Sammy
Hofsink, Quincy
Nijhof, Inger S
Goorhuis, Abraham
Kater, Arnon P
te Boekhorst, Peter A W
Swaneveld, Francis
Novotný, Věra M J
Bogers, Susanne
Welkers, Matthijs R A
Papageorgiou, Grigorios
Rijnders, Bart J
Heijmans, Jarom
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title_full Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title_fullStr Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title_full_unstemmed Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title_short Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
title_sort hyperimmune globulin for severely immunocompromised patients hospitalized with coronavirus disease 2019: a randomized, controlled trial
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384649/
https://www.ncbi.nlm.nih.gov/pubmed/35921542
http://dx.doi.org/10.1093/infdis/jiac334
work_keys_str_mv AT huygenssammy hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT hofsinkquincy hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT nijhofingers hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT goorhuisabraham hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT katerarnonp hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT teboekhorstpeteraw hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT swaneveldfrancis hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT novotnyveramj hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT bogerssusanne hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT welkersmatthijsra hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT papageorgiougrigorios hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT rijndersbartj hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial
AT heijmansjarom hyperimmuneglobulinforseverelyimmunocompromisedpatientshospitalizedwithcoronavirusdisease2019arandomizedcontrolledtrial

Ejemplares similares